The generic of Invega Sustenna is expected to become available after 26 January, 2031. This release comes as the result of the expiry of its patent, US9439906, which is set to expire on the said date.
Invega Sustenna is typically used in the treatment of schizophrenia and schizoaffective disorder. It can be administered as a monotherapy or as an adjunct to mood stabilizers or antidepressants. The drug delivers its effect through a unique dosing regimen, which includes two loading doses of paliperidone palmitate followed by maintenance dose(s).
Invega Sustenna holds a patent, US9439906, associated with the dosing regimen utilized by the drug. The patent is set to expire on 26 January, 2031, opening the door for the release of generic versions of the Invega Sustenna. Below are the details of the patent: